Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 11.97
NAS:ATNX's Cash-to-Debt is ranked lower than
99.99% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ATNX: 11.97 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ATNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.27  Med: 8.1 Max: 15.28
Current: 11.97
1.27
15.28
Equity-to-Asset 0.76
NAS:ATNX's Equity-to-Asset is ranked lower than
99.99% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ATNX: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ATNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.64 Max: 0.76
Current: 0.76
0.52
0.76
Debt-to-Equity 0.06
NAS:ATNX's Debt-to-Equity is ranked lower than
99.99% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:ATNX: 0.06 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ATNX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.98
Current: 0.06
0.04
0.98
Altman Z-Score: 11.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -543.45
NAS:ATNX's Operating Margin % is ranked lower than
99.99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ATNX: -543.45 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ATNX' s Operating Margin % Range Over the Past 10 Years
Min: -543.45  Med: -390.45 Max: -363.65
Current: -543.45
-543.45
-363.65
Net Margin % -640.50
NAS:ATNX's Net Margin % is ranked lower than
99.99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:ATNX: -640.50 )
Ranked among companies with meaningful Net Margin % only.
NAS:ATNX' s Net Margin % Range Over the Past 10 Years
Min: -640.5  Med: -394.85 Max: -362.88
Current: -640.5
-640.5
-362.88
ROE % -233.90
NAS:ATNX's ROE % is ranked lower than
99.99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:ATNX: -233.90 )
Ranked among companies with meaningful ROE % only.
NAS:ATNX' s ROE % Range Over the Past 10 Years
Min: -233.9  Med: -98.99 Max: -51.87
Current: -233.9
-233.9
-51.87
ROA % -126.35
NAS:ATNX's ROA % is ranked lower than
99.99% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:ATNX: -126.35 )
Ranked among companies with meaningful ROA % only.
NAS:ATNX' s ROA % Range Over the Past 10 Years
Min: -126.35  Med: -59.77 Max: -42.02
Current: -126.35
-126.35
-42.02
ROC (Joel Greenblatt) % -1898.33
NAS:ATNX's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:ATNX: -1898.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ATNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1898.33  Med: -1111.86 Max: -806.3
Current: -1898.33
-1898.33
-806.3
GuruFocus has detected 2 Warning Signs with Athenex Inc $NAS:ATNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ATNX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ATNX Guru Trades in

ATNX Guru Trades in

ATNX Guru Trades in

Q2 2017

ATNX Guru Trades in Q2 2017

Paul Tudor Jones 20,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ATNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ARNA, NAS:AMRI, NAS:OMER, NAS:EPZM, NAS:XNCR, NAS:FPRX, NAS:ZIOP, NAS:RGNX, NAS:EDIT, NAS:BYSI, NAS:ENTA, NAS:SPPI, NAS:ITCI, NAS:KERX, NAS:ACOR, NAS:ADRO, NAS:DERM, NAS:TGTX, NAS:VNDA, NAS:NTLA » details
Traded in other countries:2MT.Germany,
Headquarter Location:USA
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company's mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments, Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China.

Ratios

vs
industry
vs
history
PB Ratio 8.06
ATNX's PB Ratio is ranked lower than
99.99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ATNX: 8.06 )
Ranked among companies with meaningful PB Ratio only.
ATNX' s PB Ratio Range Over the Past 10 Years
Min: 6.63  Med: 7.73 Max: 8.98
Current: 8.06
6.63
8.98
PS Ratio 82.48
ATNX's PS Ratio is ranked lower than
99.99% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ATNX: 82.48 )
Ranked among companies with meaningful PS Ratio only.
ATNX' s PS Ratio Range Over the Past 10 Years
Min: 68.09  Med: 79.36 Max: 92.25
Current: 82.48
68.09
92.25
EV-to-EBIT -10.30
ATNX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ATNX: -10.30 )
Ranked among companies with meaningful EV-to-EBIT only.
ATNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.15  Med: -7.6 Max: -6.4
Current: -10.3
-11.15
-6.4
EV-to-EBITDA -10.56
ATNX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ATNX: -10.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.41  Med: -7.8 Max: -6.6
Current: -10.56
-11.41
-6.6
EV-to-Revenue 42.98
ATNX's EV-to-Revenue is ranked lower than
99.99% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ATNX: 42.98 )
Ranked among companies with meaningful EV-to-Revenue only.
ATNX' s EV-to-Revenue Range Over the Past 10 Years
Min: 36.9  Med: 43.9 Max: 51.9
Current: 42.98
36.9
51.9
Current Ratio 3.78
ATNX's Current Ratio is ranked lower than
99.99% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ATNX: 3.78 )
Ranked among companies with meaningful Current Ratio only.
ATNX' s Current Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.78 Max: 3.78
Current: 3.78
1.17
3.78
Quick Ratio 3.43
ATNX's Quick Ratio is ranked lower than
99.99% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ATNX: 3.43 )
Ranked among companies with meaningful Quick Ratio only.
ATNX' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 2.57 Max: 3.52
Current: 3.43
0.98
3.52
Days Inventory 125.69
ATNX's Days Inventory is ranked lower than
99.99% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. ATNX: 125.69 )
Ranked among companies with meaningful Days Inventory only.
ATNX' s Days Inventory Range Over the Past 10 Years
Min: 69.38  Med: 79.87 Max: 125.69
Current: 125.69
69.38
125.69
Days Sales Outstanding 96.10
ATNX's Days Sales Outstanding is ranked lower than
99.99% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ATNX: 96.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.32  Med: 74.82 Max: 100.31
Current: 96.1
49.32
100.31
Days Payable 226.08
ATNX's Days Payable is ranked lower than
99.99% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ATNX: 226.08 )
Ranked among companies with meaningful Days Payable only.
ATNX' s Days Payable Range Over the Past 10 Years
Min: 132.8  Med: 153.41 Max: 226.08
Current: 226.08
132.8
226.08

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 20.52
ATNX's Price-to-Net-Cash is ranked lower than
99.99% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ATNX: 20.52 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 0 Max: 22.07
Current: 20.52
0
22.07
Price-to-Net-Current-Asset-Value 15.03
ATNX's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ATNX: 15.03 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 0 Max: 16.16
Current: 15.03
0
16.16
Price-to-Tangible-Book 13.25
ATNX's Price-to-Tangible-Book is ranked lower than
99.99% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ATNX: 13.25 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14.25
Current: 13.25
0
14.25
Price-to-Median-PS-Value 1.04
ATNX's Price-to-Median-PS-Value is ranked lower than
99.99% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ATNX: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.12
Current: 1.04
0
1.12
Earnings Yield (Greenblatt) % -9.72
ATNX's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ATNX: -9.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.6  Med: -13.1 Max: -8.98
Current: -9.72
-15.6
-8.98

More Statistics

Revenue (TTM) (Mil) $14.37
EPS (TTM) $ -4.11
Short Percentage of Float1.47%
52-Week Range $11.21 - 20.79
Shares Outstanding (Mil)57.06

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 28 32 36 74
EPS ($) -2.10 -1.02 -1.00 -1.06
EPS without NRI ($) -2.10 -1.02 -1.00 -1.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:ATNX

Headlines

Articles On GuruFocus.com
Athenex, Inc. Added to Russell 2000® and Russell 3000® Indexes Sep 18 2017 
Athenex, Inc. Announces Grant Disbursement Agreement with New York State for Dunkirk Facility Sep 12 2017 
CORRECTING and REPLACING: Athenex, Inc. Sep 11 2017 
ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex (TXL™) in the United Sep 11 2017 
Athenex Pharmaceutical Division and SunGen Pharma Announce Terbutaline Sulfate Injection Product Lau Aug 31 2017 
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Three New Sterile Injectable Products f Aug 10 2017 
Athenex Announces Recent Product Launches in Commercial Business Aug 01 2017 
Athenex, Inc. to Report Second Quarter 2017 Earnings Results on August 14, 2017 Jul 31 2017 
Athenex, Inc. Announces Approval of Tax Incentives from State of New York for the Dunkirk Facility Jul 27 2017 
Athenex, Inc. Announces Commencement of Patient Enrollment for Oraxol-plus-Ramucirumab Phase 1b Clin Jul 19 2017 

More From Other Websites
Athenex, Inc. Added to Russell 2000® and Russell 3000® Indexes Sep 18 2017
Athenex, Inc. breached its 50 day moving average in a Bearish Manner : ATNX-US : September 14, 2017 Sep 14 2017
CORRECTING and REPLACING: Athenex, Inc. Sep 11 2017
Athenex, Inc. – Value Analysis (NASDAQ:ATNX) : September 6, 2017 Sep 05 2017
Athenex, Inc. breached its 50 day moving average in a Bullish Manner : ATNX-US : September 1, 2017 Sep 01 2017
Athenex Pharmaceutical Division and SunGen Pharma Announce Terbutaline Sulfate Injection Product... Aug 31 2017
Athenex, Inc. Announces Second Quarter 2017 Results Aug 14 2017
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Three New Sterile Injectable Products... Aug 10 2017
Rand Capital Announces Second Quarter 2017 Results Aug 07 2017
Athenex Announces Recent Product Launches in Commercial Business Aug 01 2017
Athenex, Inc. to Report Second Quarter 2017 Earnings Results on August 14, 2017 Jul 31 2017
Athenex, Inc. Announces Approval of Tax Incentives from State of New York for the Dunkirk Facility Jul 27 2017
[$$] Clinical Development News, July 17-21 Jul 21 2017
IPO Market Back On Track: ETFs to Tap Jul 12 2017
Athenex Pharmaceutical Division Receives FDA Clearance to Import Sodium Bicarbonate 8.4% Injection... Jul 12 2017
Athenex Wins Big on Chinese Cancer Drug Jul 05 2017
Athenex, Inc. Announces Submission of Investigational New Drug Application of Oraxol to Chinese FDA Jul 05 2017
IPO Market Reignites With Strong Quarterly Performance Jun 30 2017
IPOs This Week: Cable Company Altice Leads a Busy Week Jun 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}